| Autor: |
Combs CA; Pediatrix Center for Research, Education, Quality & Safety, Sunrise, FL 33323, USA., Zupancic JAF; Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA., Walker M; Statistics Consultant, Carlsbad, CA 92009, USA., Shi J; Statistics Consultant, Carlsbad, CA 92009, USA. |
| Abstrakt: |
Our objective was to evaluate whether pregnancy is prolonged by the use of a proteomics-based maternal serum screening test followed by treatment interventions. This is a secondary analysis of the PREVENT-PTB randomized trial comparing screening with the PreTRM test versus no screening. The primary trial analysis found no significant between-group difference in the preterm birth rate. Rather than considering a dichotomous outcome (preterm versus term), we treated gestational age at birth as a continuous variable using survival analysis. We also evaluated between-group difference in NICU length of stay and duration of respiratory support. Results indicated that pregnancy was significantly prolonged in subjects screened with the PreTRM test compared to controls (adjusted hazard ratio 0.53, 95% confidence interval 0.36-0.78, p < 0.01). Newborns of screened subjects had significantly shorter NICU stays but no significant decrease in duration of respiratory support. In the PreTRM screen-positive group, interventions that were associated with pregnancy prolongation included care management and low-dose aspirin but not 17-hydroxyprogesterone caproate. We conclude that screening with the PreTRM test followed by interventions for screen-positive pregnancies may prolong pregnancy and reduce NICU LOS, but these observations need to be confirmed by additional research. |
